Cyclacel's sapacitabine fails in Phase III AML trial
By Jaime De Leon | Feb 23, 2017 | 11:25 PM GMT
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine (CYC682) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute
Read the full 317 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury